Literature DB >> 3365691

Differential repair of platinum-DNA adducts in human bladder and testicular tumor continuous cell lines.

P Bedford1, A M Fichtinger-Schepman, S A Shellard, M C Walker, J R Masters, B T Hill.   

Abstract

The formation and removal of four platinum-DNA adducts were immunochemically quantitated in cultured cells derived from a human bladder carcinoma cell line (RT112) and from two lines derived from germ cell tumors of the testis (833K and SUSA), following exposure in vitro to 16.7 microM (5 micrograms/ml) cisplatin. RT112 cells were least sensitive to the drug and were proficient in the repair of all four adducts, whereas SUSA cells, which were 5-fold more sensitive, were deficient in the repair of DNA-DNA intrastrand cross-links in the sequences pApG and pGpG. Despite expressing a similar sensitivity to SUSA cells, 833K cells were proficient in the repair of all four adducts, although less so than the RT112 bladder tumor cells. In addition, SUSA cells were unable to repair DNA-DNA interstrand cross-links whereas 50-85% of these lesions were removed in RT112 and 833K cells 24 h following drug exposure. It is possible that the inability of SuSa cells to repair platinated DNA may account for their hypersensitivity to cisplatin.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3365691

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  29 in total

1.  Pre-clinical activity of taxol in non-seminomatous germ cell tumor cell lines and nude mouse xenografts.

Authors:  T A Dunn; V Grünwald; C Bokemeyer; J Casper
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

2.  Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines.

Authors:  T A Dunn; H J Schmoll; V Grünwald; C Bokemeyer; J Casper
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

3.  Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation.

Authors:  R J Parker; A Eastman; F Bostick-Bruton; E Reed
Journal:  J Clin Invest       Date:  1991-03       Impact factor: 14.808

4.  Recognition of DNA alterations by the mismatch repair system.

Authors:  G Marra; P Schär
Journal:  Biochem J       Date:  1999-02-15       Impact factor: 3.857

5.  Differential human nucleotide excision repair of paired and mispaired cisplatin-DNA adducts.

Authors:  J G Moggs; D E Szymkowski; M Yamada; P Karran; R D Wood
Journal:  Nucleic Acids Res       Date:  1997-02-01       Impact factor: 16.971

Review 6.  Role of DNA repair in the mechanisms of cell resistance to alkylating agents and cisplatin.

Authors:  P Calsou; B Salles
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

7.  Testicular Germ Cell Tumors: A Paradigm for the Successful Treatment of Solid Tumor Stem Cells.

Authors:  Caryl J Giuliano; Sarah J Freemantle; Michael J Spinella
Journal:  Curr Cancer Ther Rev       Date:  2006-08-01

8.  Repair synthesis by human cell extracts in DNA damaged by cis- and trans-diamminedichloroplatinum(II).

Authors:  J Hansson; R D Wood
Journal:  Nucleic Acids Res       Date:  1989-10-25       Impact factor: 16.971

9.  Repair synthesis by human cell extracts in cisplatin-damaged DNA is preferentially determined by minor adducts.

Authors:  P Calsou; P Frit; B Salles
Journal:  Nucleic Acids Res       Date:  1992-12-11       Impact factor: 16.971

Review 10.  Signaling and drug sensitivity.

Authors:  R D Christen; S Isonishi; J A Jones; A P Jekunen; D K Hom; R Kröning; D P Gately; F B Thiebaut; G Los; S B Howell
Journal:  Cancer Metastasis Rev       Date:  1994-06       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.